[go: up one dir, main page]

PE20090971A1 - Regimenes de inmunoterapia dependientes del estado apoe - Google Patents

Regimenes de inmunoterapia dependientes del estado apoe

Info

Publication number
PE20090971A1
PE20090971A1 PE2008001792A PE2008001792A PE20090971A1 PE 20090971 A1 PE20090971 A1 PE 20090971A1 PE 2008001792 A PE2008001792 A PE 2008001792A PE 2008001792 A PE2008001792 A PE 2008001792A PE 20090971 A1 PE20090971 A1 PE 20090971A1
Authority
PE
Peru
Prior art keywords
ala
apoe
state dependent
apoe4
refers
Prior art date
Application number
PE2008001792A
Other languages
English (en)
Inventor
Ronald Black
Lars Ekman
Ivan Lieberburg
Michael Grundman
Jim Callaway
Keith M Gregg
Jack Steven Jacobsen
Davinder Gill
Lioudmila Tchistiakova
Angela M Widom
Original Assignee
Wyeth Corp
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Elan Pharma Int Ltd filed Critical Wyeth Corp
Publication of PE20090971A1 publication Critical patent/PE20090971A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00Subject matter not provided for in other groups of this subclass
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Business, Economics & Management (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO 3D6 DE RATON TAL COMO BAPINEUZUMAB CARACTERIZADO POR QUE EN LAS POSICIONES 234, 235 Y 237 EN LA REGION CONSTANTE DE LA CADENA PESADA SON OCUPADOS POR ALA, ALA, ALA. TAMBIEN SE REFIERE A UN REGIMEN DE TRATAMIENTO DE INMUNOTERAPIA PARA PACIENTES QUE PRESENTAN EL GENOTIPO ApoE4 CERO (PACIENTE NO PORTADOR ApoE4) QUE COMPRENDE LA ADMINISTRACION DE UN SEGUNDO ANTICUERPO QUE ES UNA VARIANTE DE l234A, L235A, G237A DE BAPINEUZUMAB SIENDO UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER Y ENFERMEDADES SIMILARES
PE2008001792A 2007-10-17 2008-10-17 Regimenes de inmunoterapia dependientes del estado apoe PE20090971A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99942307P 2007-10-17 2007-10-17
US8382708P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
PE20090971A1 true PE20090971A1 (es) 2009-07-02

Family

ID=40568093

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001792A PE20090971A1 (es) 2007-10-17 2008-10-17 Regimenes de inmunoterapia dependientes del estado apoe

Country Status (32)

Country Link
US (3) US9644025B2 (es)
EP (2) EP2207565B1 (es)
JP (2) JP5745853B2 (es)
KR (1) KR101197839B1 (es)
CN (2) CN107090032A (es)
AR (1) AR071732A1 (es)
AU (1) AU2008311823A1 (es)
BR (1) BRPI0818000A2 (es)
CA (2) CA2940337A1 (es)
CL (1) CL2008003089A1 (es)
CO (1) CO6331295A2 (es)
CY (1) CY1116552T1 (es)
DK (1) DK2207565T3 (es)
EA (2) EA201590833A1 (es)
ES (1) ES2547230T3 (es)
HK (1) HK1217709A1 (es)
HR (1) HRP20150790T1 (es)
HU (1) HUE025684T2 (es)
IL (1) IL205127A (es)
JO (1) JO3076B1 (es)
MX (1) MX2010004250A (es)
MY (1) MY156454A (es)
PA (1) PA8800801A1 (es)
PE (1) PE20090971A1 (es)
PL (1) PL2207565T3 (es)
PT (1) PT2207565E (es)
RS (1) RS54130B1 (es)
SG (2) SG186649A1 (es)
SI (1) SI2207565T1 (es)
TW (2) TW201206479A (es)
WO (1) WO2009052439A2 (es)
ZA (1) ZA201002544B (es)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
EP1797182A2 (en) * 2004-10-05 2007-06-20 Wyeth a Corporation of the State of Delaware Methods and compositions for improving recombinant protein production
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
NZ565044A (en) 2005-06-17 2010-05-28 Elan Pharma Int Ltd Methods of purifying anti A beta antibodies with calcium chloride
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
IN2014DN10515A (es) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Cdrのアミノ酸置換により抗体の等電点を改変する方法
KR101922788B1 (ko) 2007-09-26 2018-11-27 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
US20100297013A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2011133919A1 (en) * 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
EP2431393B1 (en) 2009-05-15 2018-05-02 Chugai Seiyaku Kabushiki Kaisha Anti-axl antibody
CN102686610A (zh) 2009-06-18 2012-09-19 辉瑞公司 抗刻缺蛋白-1抗体
GB0912394D0 (en) * 2009-07-16 2009-08-26 Univ Birmingham Screening methods
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
HRP20161542T1 (hr) 2009-11-30 2016-12-30 Janssen Biotech, Inc. MUTIRANA Fc ANTITIJELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
US9102717B2 (en) 2010-03-01 2015-08-11 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
SG184820A1 (en) * 2010-04-13 2012-11-29 Baxter Int Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease
RU2607368C2 (ru) * 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
PT2647707T (pt) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de toxicidade
BR112013015122A2 (pt) 2010-12-15 2017-05-30 Wyeth Llc anticorpos anti-notch1
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
CN103702682A (zh) * 2011-04-21 2014-04-02 科罗拉多州立大学董事会法人团体 治疗视神经脊髓炎的组合物和方法
CA2838952C (en) * 2011-06-13 2020-11-24 Stefan Bassarab Anti-psgl-1 antibodies and uses thereof
JP5404750B2 (ja) * 2011-11-22 2014-02-05 シャープ株式会社 認知症ケア支援方法、認知症情報出力装置、認知症ケア支援システム、及びコンピュータプログラム
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
RU2019108429A (ru) * 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
PL2994160T3 (pl) * 2013-05-06 2019-10-31 Baxalta Inc Leczenie subpopulacji osób z chorobą alzheimera z użyciem połączonej immunoglobuliny g
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
IL296026B2 (en) 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR20160104636A (ko) 2014-01-15 2016-09-05 에프. 호프만-라 로슈 아게 단백질 A-결합이 개선된 Fc-영역 변이체
KR20240094017A (ko) * 2014-02-08 2024-06-24 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
PL3102230T3 (pl) * 2014-02-08 2021-11-15 F.Hoffmann-La Roche Ag Sposoby leczenia choroby Alzheimera
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗pd−l1抗体並びにその治療及び診断のための使用
KR102524920B1 (ko) 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
RU2722212C9 (ru) 2014-08-05 2020-07-23 СиБи ТЕРЕПЬЮТИКС, ИНК. Анти-pd-l1 антитела
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
IL256989B (en) 2015-08-07 2022-08-01 Alx Oncology Inc Constructs with a sirp-alpha site or a variant thereof
EP3347002B1 (en) 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3374381A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
CN108350050A (zh) * 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中的表位及其构象选择性抗体
MY197345A (en) * 2015-11-25 2023-06-14 Visterra Inc Antibody molecules to april and uses thereof
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
CN108712911A (zh) * 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
CN116333108A (zh) 2016-07-18 2023-06-27 英属哥伦比亚大学 淀粉样蛋白β的抗体
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
CN110662532A (zh) * 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
PL3658589T3 (pl) 2017-07-26 2024-03-18 Forty Seven, Inc. Przeciwciała anty-sirp-alfa i powiązane sposoby
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
KR20200118092A (ko) * 2018-02-06 2020-10-14 밴쿠버 바이오테크 리미티드 GnRH 길항제로서 GHR-106 단일 클론 항체의 용도
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
US12111324B2 (en) 2018-04-10 2024-10-08 Quanterix Corporation Quantification of biomarkers present in dried physiological samples
WO2019241430A2 (en) * 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
CN112805031A (zh) * 2018-07-24 2021-05-14 卫材R&D管理有限公司 阿尔茨海默病的治疗及预防方法
CN121248772A (zh) * 2018-08-17 2026-01-02 Ab工作室有限公司 催化抗体和其使用方法
JP2021534769A (ja) 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
AU2019336197A1 (en) 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
AU2019397436A1 (en) 2018-12-10 2021-07-22 The General Hospital Corporation Cromolyn esters and uses thereof
CN113874051A (zh) * 2019-02-27 2021-12-31 安吉克公司 包含抗tm4sf1抗体的抗体-药物缀合物及其使用方法
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022004678A (es) * 2019-10-22 2022-08-15 Biogen Ma Inc Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
US20230340119A1 (en) * 2019-12-05 2023-10-26 Arbele Corp Composition of triax antibodies and method of making and using thereof
IL297023A (en) 2020-04-06 2022-12-01 Massachusetts Gen Hospital Methods for treating inflammatory conditions caused by the corona virus
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
CN114605532B (zh) * 2022-05-07 2022-08-23 北京第一生物化学药业有限公司 抗β-淀粉样蛋白抗体及其用途
CN121001728A (zh) * 2023-04-04 2025-11-21 菲诺尼特公司 用于治疗神经退行性疾病的基因型特异性方法和系统
CN119400414B (zh) * 2024-10-28 2025-10-24 重庆邮电大学 一种阿尔兹海默症风险预测方法、装置及系统

Family Cites Families (457)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096318A (en) 1973-05-07 2000-08-01 The Ohio State University Antigenically modified HCG polypeptides
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5158769A (en) 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4713366A (en) 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
US5096706A (en) 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPS62267297A (ja) 1986-05-15 1987-11-19 Tokyo Met Gov Seishin Igaku Sogo Kenkyusho 老人斑反応性モノクロ−ナル抗体、それを産生する細胞株及び該モノクロ−ナル抗体の製造方法
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5220013A (en) 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
DE3702789A1 (de) 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
US4912206A (en) 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JPS63245689A (ja) 1987-03-31 1988-10-12 Suntory Ltd ヒトアミロイド関連蛋白モノクロ−ナル抗体
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
EP0359783B2 (en) 1987-06-24 2002-04-17 Autoimmune, Inc. Treatment of autoimmune diseases by oral administration of autoantigens
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US4966753A (en) 1987-08-18 1990-10-30 Molecular Rx, Inc. Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
WO1989003687A1 (en) 1987-10-23 1989-05-05 Genetics Institute, Inc. Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
AU3056289A (en) 1988-01-13 1989-08-11 Mclean Hospital Corporation, The Genetic constructs containing the alzheimer brain amyloid gene
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
JPH04501719A (ja) 1988-11-10 1992-03-26 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド ポリペプチド
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5227159A (en) 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0319929A (ja) 1989-06-14 1991-01-29 Asahi Chem Ind Co Ltd オープンエンド紡績の糸
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
DK0506785T3 (da) 1989-12-20 2000-07-24 Autoimmune Inc Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
HUT61896A (en) 1990-03-02 1993-03-29 Autoimmune Inc Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases
EP0451700A1 (en) 1990-04-10 1991-10-16 Miles Inc. Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
EP0527823A1 (en) 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
JP2703096B2 (ja) 1990-04-26 1998-01-26 三菱重工業株式会社 コンベア付きロボットシステムの教示方法
DE69126304T2 (de) 1990-04-27 1997-09-04 Mcmichael, John, Delanson, N.Y. Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH0415492A (ja) 1990-05-10 1992-01-20 Mitsubishi Electric Corp 磁石発電機の冷却ファンおよびその製造方法
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
WO1991019810A1 (en) 1990-06-15 1991-12-26 California Biotechnology Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
EP0537247A4 (en) 1990-06-19 1993-09-08 Immuvax Nonpathogenic variant virus
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5702906A (en) 1990-09-25 1997-12-30 Genentech, Inc. Antibodies to neurotrophic factor-4 (NT-4)
JPH06502071A (ja) 1990-09-28 1994-03-10 ジ・アップジョン・カンパニー アルツハイマーのアミロイド前駆遺伝子を有するトランスジェニック動物
CA2093022C (en) 1990-10-05 2005-02-22 Michael W. Fanger Targeted immunostimulation with bispecific reagents
ES2258261T3 (es) 1990-10-15 2006-08-16 Autoimmune, Inc. Tratamiento de enfermedades autoinmunes por administracion oral de autoantigenos.
GB9023352D0 (en) 1990-10-26 1990-12-05 Lynxvale Ltd Vaccinia vectors,vaccinia genes and expression products thereof
EP0517895B1 (en) 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP0568575B2 (en) 1991-01-21 2010-11-03 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
UA40570C2 (uk) 1991-03-01 2001-08-15 Меріал Спосіб виробництва м'яса свиней, великої та малої рогатої худоби, що має поліпшені органолептичні властивості, і набір для анти-лгрг вакцинації
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
ATE182791T1 (de) 1991-05-08 1999-08-15 Schweiz Serum & Impfinst Wiederhergestellte influenza-virosomen mit immunostimulierenden und immunoverstärkenden eigenschaften und diese enthaltende impfstoffe
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
AU671093B2 (en) 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
JP3712260B2 (ja) 1992-02-28 2005-11-02 オートイミューン インク 自己免疫疾患のバイスタンダー抑制
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0561087B1 (en) 1992-03-20 1999-08-04 N.V. Innogenetics S.A. Mutated form of the beta-amyloid precursor protein gene
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
DK0652758T3 (da) 1992-06-18 2000-05-08 Harvard College Diferitoxin-vacciner
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
WO1994001772A1 (en) 1992-07-13 1994-01-20 The Children's Medical Center Corporation SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2127829T3 (es) 1992-07-31 1999-05-01 Medeva Holdings Bv Expresion de proteinas recombinantes fusionadas en bacterias atenuadas.
US6261569B1 (en) 1992-08-27 2001-07-17 Deakin Research Limited Retro-, inverso- and retro-inverso synthetic peptide analogues
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
AU5358494A (en) 1992-10-13 1994-05-09 Duke University Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein
PT1298436E (pt) 1992-10-26 2010-10-21 Lilly Co Eli Métodos para a identificação de compostos inibidores da libertação de péptido beta-amilóide (bap)
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US5972336A (en) 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0680338B1 (en) 1993-01-22 2003-04-16 Sloan-Kettering Institute For Cancer Research Ganglioside-klh conjugate vaccines with qs-21
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP1308461A3 (en) 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
DE69435075T2 (de) 1993-03-17 2009-02-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
EP0690722B1 (en) 1993-03-18 2004-06-30 Cytimmune Sciences, Inc. Composition and method for reducing toxicity of biologically-active factors
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
NO940913L (no) 1993-03-26 1994-09-27 Bristol Myers Squibb Co Preparater for kontrollert frigivelse av biologisk aktiv TGF-
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
EP0705109B2 (en) 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
WO1994028412A1 (en) 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
CA2164298A1 (en) 1993-06-04 1994-12-22 Richard A. Young Stress proteins and uses therefor
GR1001607B (el) 1993-06-10 1994-06-30 Lucet Beatrice Yvette Michele Πλωτό σύστημα υποστήριξης φραγμάτων με απορροφητικά υλικά για την αντιρρυπαντική προστασία κλειστών ή ημίκλειστων υδάτινων συστημάτων από επιπλέοντες υδρογονάν?ρακες.
US5464823A (en) 1993-07-20 1995-11-07 The Regents Of The University Of California Mammalian antibiotic peptides
ATE215124T1 (de) 1993-07-30 2002-04-15 Medeva Holdings Bv Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
WO1995005393A2 (en) 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides
US6538624B1 (en) * 1993-08-20 2003-03-25 Seiko Epson Corporation Head-mounted image display apparatus
EP0714308A4 (en) 1993-08-26 1998-07-29 Univ California METHOD, COMPOSITIONS AND DEVICES FOR THE ADMINISTRATION OF NAKED POLYNUCLEOTIDS, WHICH ENCODE FOR BIOLOGICALLY ACTIVE PEPTIDES
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
WO1995006407A1 (en) 1993-08-30 1995-03-09 The Regents Of The University Of California Novel component of amyloid in alzheimer's disease and methods for use of same
AP583A (en) 1993-09-07 1997-04-14 Smithkline Beecham Corp Recombination IL4 antibodies useful in treatment of IL4 mediated disorders.
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
ATE213507T1 (de) 1993-10-20 2002-03-15 Univ Duke Methode zur bindung von material an das beta- amyloid-peptid
DK0724431T3 (da) 1993-10-22 2003-01-06 Genentech Inc Fremgangsmåder og sammensætninger til mikroindkapsling af adjuvanser
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
AU1909695A (en) 1994-01-27 1995-08-15 Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
AU692237B2 (en) 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
CA2191101C (en) 1994-05-25 2001-08-07 Ellis L. Kline Materials and methods for treatment of plaquing diseases
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
CN1180843C (zh) 1994-07-27 2004-12-22 昆士兰医学研究所 多表位疫苗
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
EP0784684B8 (en) 1994-09-16 2008-03-26 Cancer Research Institute of Contra Costa RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
ATE216590T1 (de) 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
CA2215162A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
AU6113896A (en) 1995-06-05 1996-12-24 Brigham And Women's Hospital Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
CA2221986A1 (en) 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
US5910427A (en) 1995-06-22 1999-06-08 La Jolla Institute For Allergy And Immunology Antigen non-specific glycosylation inhibiting factor derivatives
ES2174027T3 (es) 1995-06-30 2002-11-01 American Cyanamid Co Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.
WO1997003192A2 (en) 1995-07-07 1997-01-30 Darwin Molecular Corporation Chromosome 1 gene and gene products related to alzheimer's disease
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
AU6898996A (en) 1995-08-21 1997-03-12 Cytrx Corporation Compositions and methods for growth promotion
DE852011T1 (de) 1995-09-14 2001-10-11 Scripps Res Inst La Jolla Für natives prp-sc spezifische antikörper
US5731284A (en) 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
AU3804995A (en) 1995-10-10 1997-04-30 Novartis Ag Melanoma-associated protein
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
PT859959E (pt) 1995-11-10 2003-12-31 Elan Corp Plc Peptidos que aumentam o transporte atraves dos tecidos e metodos para a sua identificacao e utilizacao
WO1997018855A1 (en) 1995-11-21 1997-05-29 Eduard Naumovich Lerner Device for enhanced delivery of biologically active substances and compounds in an organism
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
JPH09178743A (ja) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性appの定量法
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
JP2000505306A (ja) 1996-02-26 2000-05-09 モルフォシス・アクチェンゲゼルシャフト 2つまたはそれ以上の相互作用性(ポリ)ペプチドをコードする核酸配列の新規同定方法
US6150091A (en) 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
US6372225B1 (en) 1996-03-23 2002-04-16 The Research Foundation Of Microbial Diseases Of Osaka University Tetanus toxin functional fragment antigen and tetanus vaccine
WO1997037031A1 (en) 1996-03-29 1997-10-09 University Of Otago Parapoxvirus vectors
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
CA2250814A1 (en) 1996-04-03 1997-10-09 Anergen, Inc. Cyclic peptide vaccines for treatment and prevention of diabetes
JP2002506419A (ja) 1996-04-19 2002-02-26 アメリカ合衆国 A型肝炎ウイルスポリタンパク質の抗原反応性領域
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
ATE253593T1 (de) 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
GB9617616D0 (en) 1996-08-22 1996-10-02 Osteometer Biotech As Assaying protein fragments in body fluids
DK0929574T3 (da) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en) 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
US6962984B2 (en) 1996-12-05 2005-11-08 Nihon University IgA nephropathy-related DNA
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
EE9900481A (et) 1997-03-03 2000-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5798102A (en) 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
JP5087758B2 (ja) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート アジュバントとして非メチル化CpGジヌクレオチドを含む核酸の使用
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CA2286305A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US7118750B1 (en) 1997-04-15 2006-10-10 Pharmexa A/S Modified TNF-alpha molecules, DNA encoding such and vaccines comprising such modified TNF-alpha and DNA
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293510B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici per la trasformazione in vivo di profarmaci di corticosteroidi
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
WO1999006545A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体(ポリ)ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
DE69840962D1 (de) 1997-08-29 2009-08-20 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
US6175057B1 (en) 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6118044A (en) 1997-11-14 2000-09-12 Sankyo Company, Limited Transgenic animal allergy models and methods for their use
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
ES2253839T3 (es) 1997-12-03 2006-06-01 Neuralab, Ltd. Supresion de cambios relacionados con amiloide beta en la enfermedad de alzheimer.
WO1999027911A1 (fr) 1997-12-03 1999-06-10 Fujisawa Pharmaceutical Co., Ltd. Medicament en pastilles souples et procede de fabrication
FR2777015B3 (fr) 1998-02-23 2000-09-15 Financ De Biotechnologie Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20050059591A1 (en) 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
JP2002512776A (ja) 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1080110A2 (en) 1998-05-19 2001-03-07 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
IL139095A0 (en) 1998-05-21 2001-11-25 Univ Tennessee Res Corp Methods for amyloid removal using anti-amyloid antibodies
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6432710B1 (en) 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
CZ20011049A3 (cs) 1998-10-05 2002-08-14 Pharmexa A/S Imunogenní kompozice a způsob selekce imunogenního analogu
WO2000023082A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US7112661B1 (en) 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
EP1148891B1 (en) 1999-01-19 2004-03-17 PHARMACIA & UPJOHN COMPANY Method of packaging an oxidation sensitive medicinal substance
WO2000043039A1 (en) 1999-01-22 2000-07-27 Matthew John During Vaccine-mediated treatment of neurological disorders
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
US7629311B2 (en) 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US20040038317A1 (en) 1999-03-15 2004-02-26 Kalobios, Inc. Breakpoint fusion fragment complementation system
US7282570B2 (en) 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE384077T1 (de) 1999-05-05 2008-02-15 Neurochem Int Ltd Stereoselektive antifibrillogene peptide
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
PE20010212A1 (es) 1999-06-01 2001-02-22 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
DK1409654T3 (da) 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
US6596474B1 (en) 1999-07-01 2003-07-22 Scios Inc. Prevention and treatment of amyloid-associated disorders
JP2003522735A (ja) 1999-07-15 2003-07-29 ジェネティクス インスティチュート,エルエルシー Il−11に関する組成物
EP1571158B1 (en) 1999-08-04 2009-10-14 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0016022A (pt) 1999-11-29 2002-08-06 Neurochem Inc Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
PT1237930E (pt) 1999-12-08 2007-02-28 Intellect Neurosciences Inc Péptidos beta amiloides quiméricos
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
KR20080017471A (ko) 2000-02-21 2008-02-26 파멕사 에이/에스 아밀로이드의 하향-조절을 위한 신규한 방법
EA008762B1 (ru) 2000-02-21 2007-08-31 Фармекса А/С АНАЛОГ АУТОЛОГИЧНОГО Аβ ИЛИ АРР ЖИВОТНОГО И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
TR200202799T3 (tr) 2000-02-24 2003-03-21 Washington University St.Louis AB peptidini sekanslayan insanlaştırılmış antikorlar
US7485616B2 (en) 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis
ATE398463T1 (de) 2000-04-13 2008-07-15 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
AU7487301A (en) 2000-05-22 2001-12-03 Univ New York Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
NZ523428A (en) 2000-06-28 2008-03-28 Prana Biotechnology Ltd Neurotoxic oligomers
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
DE10038237A1 (de) 2000-08-04 2002-02-14 Aventis Res & Tech Gmbh & Co Verfahren zum Nachweis von Mutationen in Nucleotidsequenzen
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
ATE441663T1 (de) 2000-09-06 2009-09-15 Aventis Pharma Sa Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
IT1319277B1 (it) 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en) 2000-10-26 2001-11-25 Marikovsky Moshe Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
AU2002251682A1 (en) 2000-11-02 2002-08-28 Cornell Research Foundation, Inc. In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
DE60126980T2 (de) 2000-11-27 2007-11-08 Praecis Pharmaceuticals Inc., Waltham Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6900036B2 (en) 2000-12-27 2005-05-31 University Of Texas Health Science Center Houston Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
WO2002059621A2 (en) 2001-01-24 2002-08-01 Bayer Corporation Regulation of transthyretin to treat obesity
EP1251138B1 (en) 2001-04-19 2006-07-26 Hermann Dr. Schätzl Prion protein dimers useful for vaccination
AU2002258808A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
WO2002088307A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20020197258A1 (en) 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20030135035A1 (en) 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
JP2005500389A (ja) * 2001-08-17 2005-01-06 イーライ・リリー・アンド・カンパニー Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用
WO2003015691A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
JP4411068B2 (ja) * 2001-09-10 2010-02-10 アンチキャンサー インコーポレーテッド 腫瘍転移の解像度の向上
US6907297B2 (en) 2001-09-28 2005-06-14 Ethicon, Inc. Expandable intracardiac return electrode and method of use
US7781413B2 (en) 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
CN1292655C (zh) 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
EP1572894B1 (en) 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
US7335478B2 (en) 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20030157579A1 (en) 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003250110C1 (en) 2002-07-19 2008-05-29 Novartis Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
JP2006513259A (ja) 2002-07-24 2006-04-20 イノジェネティックス・ナムローゼ・フェンノートシャップ ベータ−アミロイド生成および/または凝集に関連した疾病の防止、処置および診断
US6827524B2 (en) * 2002-07-26 2004-12-07 Ingersoll-Rand Company Controller for a compacting vehicle wetting system
DE60328198D1 (de) * 2002-08-07 2009-08-13 Novartis Ag Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
US6802134B2 (en) 2002-08-09 2004-10-12 Patrick J. Allen Tapered sliding dovetail tool and kit including such tool
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
WO2004031400A2 (en) 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20060019850A1 (en) * 2002-10-31 2006-01-26 Korzenski Michael B Removal of particle contamination on a patterned silicon/silicon dioxide using dense fluid/chemical formulations
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US6787129B1 (en) 2003-01-13 2004-09-07 Zenitech Llc Castor polyester as gloss agents in anionic systems
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20040242845A1 (en) 2003-02-21 2004-12-02 Nicolau Yves Claude Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
CA2520853A1 (en) 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
CA2519408C (en) 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20060182321A1 (en) * 2003-07-07 2006-08-17 Agency For Science, Technology And Research Method and apparatus for extracting third ventricle information
WO2005014041A2 (en) 2003-07-24 2005-02-17 Novartis Ag Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
US20050123553A1 (en) 2003-07-30 2005-06-09 Alon Monsonego Amyloid beta-peptide and methods of use
US20060233788A1 (en) 2003-09-05 2006-10-19 Heiman Mark L Anti-ghrelin antibodies
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
CN1984676A (zh) 2003-12-17 2007-06-20 惠氏公司 免疫原性肽载体结合物及其生产方法
MY144231A (en) 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
WO2005065348A2 (en) 2003-12-31 2005-07-21 Kalobios, Inc. Transactivation system for mammalian cells
WO2005069970A2 (en) 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
US20050214222A1 (en) 2004-02-13 2005-09-29 Mckinnon Stuart J In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
CN102786476B (zh) 2004-03-15 2017-01-18 詹森药业有限公司 作为阿片受体调节剂的化合物
FR2871633A1 (fr) 2004-06-10 2005-12-16 France Telecom Procede de reduction du bruit de phase lors de la reception d'un signal ofdm, recepteur, programme et support
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CN101137397A (zh) 2004-07-02 2008-03-05 匹兹堡大学高等教育联邦体系 淀粉样蛋白成像作为抗淀粉样蛋白疗法的功效的替代标记物
EP1788415A4 (en) 2004-07-13 2008-11-26 Fujikura Ltd HOLES-ASSISTED TYPE FIBER AND MULTIMODE FIXED TROUGH FIBER WITH LOW TORSION LOSS
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
KR20070040824A (ko) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
GT200500255A (es) * 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
WO2006032653A2 (en) 2004-09-23 2006-03-30 Novo Nordisk A/S Device for self-care support
CN1276024C (zh) 2004-09-30 2006-09-20 北京科技大学 含缺陷管道修复补强的碳纤维复合材料和方法
EP1797182A2 (en) * 2004-10-05 2007-06-20 Wyeth a Corporation of the State of Delaware Methods and compositions for improving recombinant protein production
US20060160161A1 (en) 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
PT2343380T (pt) 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20060153772A1 (en) 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
WO2006066171A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
US8916165B2 (en) * 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
WO2006066233A1 (en) 2004-12-15 2006-06-22 Neuralab Limited An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RU2007124933A (ru) * 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
CA2607868A1 (en) 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
NZ565044A (en) * 2005-06-17 2010-05-28 Elan Pharma Int Ltd Methods of purifying anti A beta antibodies with calcium chloride
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
AU2006297173A1 (en) 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
EP3211946B1 (en) 2005-10-04 2018-09-19 Huawei Technologies Co., Ltd. A method and system for determining the group number used by mobile terminals having a same frequency band position for receiving signals in idle mode
KR20080095836A (ko) 2005-11-10 2008-10-29 로스캄프 리서치 엘엘씨 A―베타 펩티드 단편에 의한 혈관형성의 조정
EP1951892A4 (en) 2005-11-22 2009-01-14 Univ Pennsylvania ANTIBODY TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES
JP5419131B2 (ja) 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ1〜42特異的モノクローナル抗体
US8227576B2 (en) 2006-03-30 2012-07-24 Glaxo Group Limited Antibodies against amyloid-β peptide
WO2010044803A1 (en) 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TWI305843B (en) * 2006-04-24 2009-02-01 Young Optics Inc Dlp projection apparatus
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
WO2008114801A1 (en) 2007-03-12 2008-09-25 National Institute Of Radiological Sciences Pet visualization of amyloid-associated neuroinflammation in the brain
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CA2684323A1 (en) 2007-04-18 2008-10-30 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2011133919A1 (en) 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
PT2237803E (pt) 2007-12-28 2015-10-16 Prothena Biosciences Ltd Tratamento e profilaxia da amiloidose
US9839699B2 (en) 2008-09-18 2017-12-12 Yeda Research And Development Co., Ltd. Optical method for detecting Alzheimer's disease by systemic administration of curcumin
WO2011106732A1 (en) 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
US8689528B1 (en) 2011-11-08 2014-04-08 Seda Gaspari Method of packaging a plurality of tissues for dispensing

Also Published As

Publication number Publication date
HUE025684T2 (en) 2016-04-28
KR20100068301A (ko) 2010-06-22
KR101197839B1 (ko) 2012-11-05
BRPI0818000A2 (pt) 2012-12-25
EA022307B1 (ru) 2015-12-30
US20120070379A1 (en) 2012-03-22
EP2952524A1 (en) 2015-12-09
TW200932264A (en) 2009-08-01
CN107090032A (zh) 2017-08-25
CN101969988A (zh) 2011-02-09
PA8800801A1 (es) 2010-04-21
US9644025B2 (en) 2017-05-09
CL2008003089A1 (es) 2009-01-09
JP2015145419A (ja) 2015-08-13
EP2207565B1 (en) 2015-04-22
CA2702617C (en) 2016-10-04
US20090155256A1 (en) 2009-06-18
IL205127A0 (en) 2010-11-30
MX2010004250A (es) 2010-06-01
TWI581803B (zh) 2017-05-11
AU2008311823A1 (en) 2009-04-23
TW201206479A (en) 2012-02-16
CA2940337A1 (en) 2009-04-23
HK1146234A1 (en) 2011-05-27
CA2702617A1 (en) 2009-04-23
EP2207565A2 (en) 2010-07-21
JP5745853B2 (ja) 2015-07-08
EA201590833A1 (ru) 2015-08-31
DK2207565T3 (en) 2015-07-13
HRP20150790T1 (hr) 2015-08-28
MY156454A (en) 2016-02-26
JP6022636B2 (ja) 2016-11-09
SI2207565T1 (sl) 2015-08-31
EA201000644A1 (ru) 2011-04-29
IL205127A (en) 2015-08-31
WO2009052439A2 (en) 2009-04-23
US20100266505A1 (en) 2010-10-21
CO6331295A2 (es) 2011-10-20
HK1217709A1 (en) 2017-01-20
JP2011501945A (ja) 2011-01-20
WO2009052439A3 (en) 2009-06-04
ES2547230T3 (es) 2015-10-02
CY1116552T1 (el) 2017-03-15
RS54130B1 (sr) 2015-12-31
JO3076B1 (ar) 2017-03-15
PL2207565T3 (pl) 2015-10-30
SG10201607589XA (en) 2016-10-28
ZA201002544B (en) 2011-06-29
PT2207565E (pt) 2015-09-14
EP2207565A4 (en) 2012-05-02
AR071732A1 (es) 2010-07-14
SG186649A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
PE20090971A1 (es) Regimenes de inmunoterapia dependientes del estado apoe
US20230081443A1 (en) Anti-il1rap antibodies
PE20090321A1 (es) Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PE20120341A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
PE20150614A1 (es) Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
MY182680A (en) Antibody formulation and therapeutic regimens
MA34471B1 (fr) Procédés de préparation de promédicaments au phosphoramidate pur au plan diastéréomère
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20081171A1 (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cancer
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
PE20220392A1 (es) Moleculas de union a claudina-6 y usos de las mismas
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA201170475A1 (ru) Иммунотерапевтические средства против комплекса tcr
PE20121542A1 (es) Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EA201100299A1 (ru) Органические соединения
PA8852901A1 (es) Inhibidores de proteina cinasa
UA111579C2 (uk) ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
CR20110585A (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide
AR092027A1 (es) Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
PE20140230A1 (es) Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3)
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
AR092044A1 (es) Inmunoterapia mejorada
CR11817A (es) Anticuerpos anti-factor d humanizados y sus usos

Legal Events

Date Code Title Description
FG Grant, registration